Abstract
Brazil is increasingly well positioned to compete in the field of advanced therapies. In particular, five gene therapy products have been registered with ANVISA, paving the way for new proposals for clinical evaluation. Our group has invested the development of an intervention for melanoma that uses improved adenoviral vectors to deliver two genes, p14ARF and interferon-beta, which cooper…